Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma

por Seront, Emmanuel, Catala, Gaëtan, Dermine, Alexandre, Lejeune, Sarah, Rysselinck, Stephane
Publicado 2018

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metast...

por Lonez, Caroline, Verma, Bikash, Hendlisz, Alain, Aftimos, Philippe, Awada, Ahmad, Van Den Neste, Eric, Catala, Gaetan, Machiels, Jean-Pascal H, Piette, Fanny, Brayer, Jason B, Sallman, David A, Kerre, Tessa, Odunsi, Kunle, Davila, Marco L, Gilham, David E, Lehmann, Frédéric F
Publicado 2017

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

por Machiels, Jean-Pascal, Gomez-Roca, Carlos, Michot, Jean-Marie, Zamarin, Dmitriy, Mitchell, Tara, Catala, Gaetan, Eberst, Lauriane, Jacob, Wolfgang, Jegg, Anna-Maria, Cannarile, Michael A, Watson, Carl, Babitzki, Galina, Korski, Konstanty, Klaman, Irina, Teixeira, Priscila, Hoves, Sabine, Ries, Carola, Meneses-Lorente, Georgina, Michielin, Francesca, Christen, Randolph, Rüttinger, Dominik, Weisser, Martin, Delord, Jean-Pierre, Cassier, Philippe
Publicado 2020